Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06912633 · ClinicalTrials.gov registry record · Phase 2

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

A Phase 2 study of Retinitis Pigmentosa, sponsored by jCyte.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
14
Study locations

NCT06912633 is a Phase 2 study of Retinitis Pigmentosa that is actively recruiting participants, run by jCyte. The registered enrollment target is 60 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (77% lower). The trial reports 14 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06912633, a Phase 2 study of Retinitis Pigmentosa, is actively recruiting participants, sponsored by jCyte.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
14
Study locations

Study Summary

This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (6.0M jCell) compared to sham-treated controls.

Conditions Studied

Retinitis Pigmentosa

Interventions

  • BIOLOGICAL human retinal progenitor cells
  • OTHER Mock injection

Study Locations (14)

California

  • California Retina Consultants - Bakersfield
  • Retina-Vitreous Associates Medical Group - Beverly Hills
  • Gavin Herbert Eye Institute, UC Irvine - Irvine
  • Retina Consultants Medical Group - Sacramento
  • Bay Area Retina Associates - Walnut Creek

Texas

  • Retina Consultants of Texas: Bellaire Retina Center - Bellaire
  • Retina Consultants of Texas: San Antonio - San Antonio

Arizona

  • Associated Retina Consultants - Phoenix

Florida

  • Vitreo Retinal Associates - Gainesville

Georgia

  • Georgia Retina - Marietta

Illinois

  • Illinois Retina Associates - Oak Park

New Jersey

  • NJRetina - Teaneck

New York

  • Long Island Vitreoretinal Consultants - Westbury

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-06-20
Est. Completion 2026-09
Phase Phase 2

Sponsor

jCyte

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06912633

The ClinicalTrials.gov registry entry for NCT06912633 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (77% lower). The listed sponsor is jCyte, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which human retinal progenitor cells is the first listed.

NCT06912633 reports 14 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT06912633 about?

NCT06912633 is a clinical study titled "Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)". This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatme...

What is the current status of trial NCT06912633?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-06-20. Estimated completion is 2026-09.

What conditions does trial NCT06912633 study?

This clinical trial studies the following conditions: Retinitis Pigmentosa.

What interventions are being tested in trial NCT06912633?

The interventions under investigation include: human retinal progenitor cells (BIOLOGICAL), Mock injection (OTHER).

Who is sponsoring clinical trial NCT06912633?

This trial is sponsored by jCyte, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06912633 being conducted?

This trial has 14 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Retinitis Pigmentosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Retinitis Pigmentosa

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.